CoChat

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients

Open access
Muecksch, Frauke, Wise, Helen, Batchelor, Becky, Squires, Maria, Semple, Elizabeth, Richardson, Claire, McGuire, Jacqueline, Clearly, Sarah, Furrie, Elizabeth, Greig, Neil, Hay, Gordon, Templeton, Kate, Lorenzi, Julio C C, Hatziioannou, Theodora, Jenks, Sara, Bieniasz, Paul D · 2021 · The Journal of Infectious Diseases

Published version of a preprint

The DOI matches its Crossref record; 56 of the 60 references it cites were found in a registry or an index.

Abstract

Background: Understanding the longitudinal trajectory of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is crucial for diagnosis of prior infection and predicting future immunity. Methods: We conducted a longitudinal analysis of coronavirus disease 2019 convalescent patients, with neutralizing antibody assays and SARS-CoV-2 serological assay platforms using SARS-CoV-2 spike (S) or nucleocapsid (N) antigens. Results: Sensitivities of serological assays in diagnosing prior SARS-CoV-2 infection changed with time. One widely used commercial platform that had an initial sensitivity of >95% declined to 71% at 81–100 days after diagnosis. The trajectories of median binding antibody titers measured over approximately 3–4 months were not dependent on the use of SARS-CoV-2 N or S proteins as antigen. The median neutralization titer decreased by approximately 45% per month. Each serological assay gave quantitative antibody titers that were correlated with SARS-CoV-2 neutralization titers, but S-based serological assay measurements better predicted neutralization potency. Correlation between S-binding and neutralization titers deteriorated with time, and decreases in neutralization titers were not predicted by changes in S-binding antibody titers. Conclusions: Different SARS-CoV-2 serological assays are more or less well suited for surveillance versus prediction of serum neutralization potency. Extended follow-up should facilitate the establishment of appropriate serological correlates of protection against SARS-CoV-2 reinfection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiaa659

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Longitudinal analysis of serum samples from participants with coronavirus disease 2019. A, Sensitivity of the Abbott, DiaSorin, Siemens, and Roche serological assays, measured in samples collected at 4 time points after polymerase chain reaction (PCR) testing, with 95% confidence intervals (CIs). B, Relative antibody titers for the DiaSorin, Siemens, Abbott, and Roche assays at visits 1–3, normalized to visit 1 (serological assay values are reported in the assay-specific units of measurement and are expressed as % of visit 1). Horizontal lines indicates median values with 95% CIs. Statistical significance was assessed with the Wilcoxon test. C, Values for DiaSorin, Siemens, Abbott, and Roche serological assays for each participant plotted over time (each line represents 1 participant) (serological assay values are reported in the assay-specific units of measure). Assay thresholds are indicated by dotted horizontal lines. Abbreviations: AU, arbitrary units; COI, cutoff index; NS, not significant; s/c, sample to calibrator index.
Figure 1. Longitudinal analysis of serum samples from participants with coronavirus disease 2019. A, Sensitivity of the Abbott, DiaSorin, Siemens, and Roche serological assays, measured in samples collected at 4 time points after polymerase chain reaction (PCR) testing, with 95% confidence intervals (CIs). B, Relative antibody titers for the DiaSorin, Siemens, Abbott, and Roche assays at visits 1–3, normalized to visit 1 (serological assay values are reported in the assay-specific units of measurement and are expressed as % of visit 1). Horizontal lines indicates median values with 95% CIs. Statistical significance was assessed with the Wilcoxon test. C, Values for DiaSorin, Siemens, Abbott, and Roche serological assays for each participant plotted over time (each line represents 1 participant) (serological assay values are reported in the assay-specific units of measure). Assay thresholds are indicated by dotted horizontal lines. Abbreviations: AU, arbitrary units; COI, cutoff index; NS, not significant; s/c, sample to calibrator index.CC BY-NC-ND · PubMed Central
Figure 2. Neutralization activity in serum samples from participants with coronavirus disease 2019. A, Half-maximal neutralization titer (NT50) for each individual participant, measured in serum samples collected at 3 visits. Inset shows correlation of NT50 values for samples collected at each visit, with Spearman r values (P < .001). B, Relative NT50 values in serum samples obtained at visits 1–3, normalized to visit 1. Horizontal line represents median with 95% confidence interval. Statistical significance was assessed with the Wilcoxon test. C, Frequency of serum samples with NT50 values falling to various quantitative categories at each visit. D, NT50 values for each participant plotted over time (each line represents 1 participant). The limit of detection is indicated by a dotted horizontal line. Abbreviation: PCR, polymerase chain reaction.
Figure 2. Neutralization activity in serum samples from participants with coronavirus disease 2019. A, Half-maximal neutralization titer (NT50) for each individual participant, measured in serum samples collected at 3 visits. Inset shows correlation of NT50 values for samples collected at each visit, with Spearman r values (P < .001). B, Relative NT50 values in serum samples obtained at visits 1–3, normalized to visit 1. Horizontal line represents median with 95% confidence interval. Statistical significance was assessed with the Wilcoxon test. C, Frequency of serum samples with NT50 values falling to various quantitative categories at each visit. D, NT50 values for each participant plotted over time (each line represents 1 participant). The limit of detection is indicated by a dotted horizontal line. Abbreviation: PCR, polymerase chain reaction.CC BY-NC-ND · PubMed Central
Figure 3. Correlation of serological results with neutralization titers. A–D, Serological assay values for the DiaSorin (A), Siemens (B), Abbott (C) and Roche (D) assays (serological assay values are reported in the assay-specific units of measure) versus half-maximal neutralizing titer (NT50) values. Samples collected at each visit are indicated by color and are plotted individually as well as on a composite graph. Spearman r values for all visits (black) and for individual visits are indicated (P < .001). Abbreviations: AU, arbitrary units; COI, cutoff index; s/c, sample to calibrator index.
Figure 3. Correlation of serological results with neutralization titers. A–D, Serological assay values for the DiaSorin (A), Siemens (B), Abbott (C) and Roche (D) assays (serological assay values are reported in the assay-specific units of measure) versus half-maximal neutralizing titer (NT50) values. Samples collected at each visit are indicated by color and are plotted individually as well as on a composite graph. Spearman r values for all visits (black) and for individual visits are indicated (P < .001). Abbreviations: AU, arbitrary units; COI, cutoff index; s/c, sample to calibrator index.CC BY-NC-ND · PubMed Central
Figure 4. Lack of correlation of changes in serological results with changes in neutralization titers. A–D, Fold change (from visit 1 to visit 3) in serological assay values (reported in the assay-specific units of measure) for the DiaSorin (A), Siemens (B), Abbott (C), and Roche (D) assay versus fold change in half-maximal neutralizing titer (NT50) values. Spearman r and P values are shown. Abbreviations: AU, arbitrary units; COI, cutoff index; s/c, sample to calibrator index.
Figure 4. Lack of correlation of changes in serological results with changes in neutralization titers. A–D, Fold change (from visit 1 to visit 3) in serological assay values (reported in the assay-specific units of measure) for the DiaSorin (A), Siemens (B), Abbott (C), and Roche (D) assay versus fold change in half-maximal neutralizing titer (NT50) values. Spearman r and P values are shown. Abbreviations: AU, arbitrary units; COI, cutoff index; s/c, sample to calibrator index.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 4

  1. Wajnberg, SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months, medRxiv
  2. To, COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing, Clin Infect Dis
  3. Larson, A case of early reinfection with SARS-CoV-2, Clin Infect Dis
  4. To, 2020, Serum antibody profile of a patient with COVID-19 reinfection, Clin Infect Dis

Cited by

See all 309

Metadata

Authors
Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., Hay, G., Templeton, K., Lorenzi, J. C. C., Hatziioannou, T., Jenks, S., & Bieniasz, P. D.
Affiliations
  • Rockefeller University (US)
  • NHS Lothian (GB)
  • NHS Lanarkshire (GB)
  • NHS Tayside (GB)
  • Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA
  • Howard Hughes Medical Institute (US)
Corresponding author
Bieniasz, Paul D
Venue
The Journal of Infectious Diseases
Published
2020-11-03
Volume
223
Issue
3
Pages
389-398
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W3096243826
Cited by
308
References
60
Citations by year
2026: 6 · 2025: 9 · 2024: 15 · 2023: 37 · 2022: 73 · 2021: 147 · 2020: 20
FWCI
9.03
Type
journal article
Language
en
Open access
Locations
  • The Journal of Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion, cc-by-nc-nd)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
Funders
National Institute of Allergy and Infectious Diseases (R01AI078788, R37AI064003)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, serological assays, antibody titers, spike protein antigen, antibody waning, reinfection, convalescent patients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. https://app.cochat.ai/papers/10.1093/infdis/jiaa659
The paper
Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J., Clearly, S., Furrie, E., Greig, N., Hay, G., Templeton, K., Lorenzi, J. C. C., Hatziioannou, T., Jenks, S., & Bieniasz, P. D. (2021). Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaa659

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.